Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
It is a non-randomized, multi-center single-arm, open-label Simon two-stage, phase II treatment trial studying Fecal Microbiota Transplantation (FMT) + Pembrolizumab in patients with Non-small-cell lung cancer (NSCLC)
Objective response rate in the NSCLC cohort by RECIST criteria.
The objective response rate (ORR) in non-small cell lung cancer (NSCLC) was 80% (16 out of 20), successfully achieving the primary endpoint of the study (1)
The findings confirm that FMT, when used in combination with ICI, shows clinical activity. They also suggest that for FMT to provide therapeutic benefits, it …